The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | The impact of post-transplant maintenance strategies on the QoL of patients with multiple myeloma
Nico Gagelmann, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, explains the post-transplant maintenance strategies for myeloma patients in terms of quality of life (QoL). Not all patients tolerate the standard of care lenalidomide, so clinical studies must consider a multi-agent maintenance approach without neglecting QoL, especially if this treatment will not significantly prolong overall survival (OS). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
